Replies to post #20745 on Radient Pharmaceuticals Corporation fka RXPC

[guardiangel]

DCSPKA SAID

Re: dcspka post# 20744
Post # of 20746
As any objective investor can see:

William Gartner has been a very effective and busy Deal Maker for a proud owner of a "Go Daddy" website. The idea of His Detractors downplaying His Role as driving force between bringing together the Takeover Group, Provista, RXPC, Amarantus, GCDx, and Dignyte is plain silly.

Wolf Says

Don't forget William/Provista/LPath Connection you understand. CIT mb?

LPath >>>>> http://www.lpath.com/about-lpath/companysummary/

Columbo Says


March 06, 2013 11:15 ET
Lpath Signs Collaboration and License Agreement With Provista Diagnostics to Develop Cancer Diagnostics

SAN DIEGO, CA--(Marketwire - Mar 6, 2013) - Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, has signed a collaboration and license agreement to develop cancer diagnostics with Provista Diagnostics, Inc. a leader in molecular cancer diagnostics and a CLIA-accredited reference laboratory.

The collaboration will focus on the bioactive lipid lysophosphatidic acid (LPA), with the agreement granting Provista an exclusive license to Lpath's murine LPA antibodies for use in clinical laboratory applications involving the diagnoses of cancer.

Provista will initially conduct a prospective pilot study in ovarian cancer patients and Lpath will measure levels of LPA from patient plasma. Based on the results, additional studies may be conducted in ovarian and other cancers. Lpath will receive an upfront payment, research funding and development milestone payments, as well as royalties on diagnostic-product revenue.

The American Cancer Society estimates more than 22,000 new cases of ovarian cancer will be diagnosed in the United States this year, leading to 14,000 deaths. While other cancers have shown a reduction in mortality due to early detection tests and improved treatments, this has not been so with ovarian cancer, the deadliest of all gynecologic cancers.

"While our ImmuneY2™ technology platform is known for generating therapeutic antibodies against disease, it also has potential utility in diagnostic settings," said Lpath President and CEO Scott Pancoast. "So by collaborating with Provista, a leader in molecular cancer diagnostics settings, we believe we can develop tests that provide early detection of ovarian cancer and that improve treatment outcomes. This agreement also underscores the significant value and capabilities of ImmuneY2 and further reinforces the importance of bioactive lipids as disease-relevant molecules."

Dr. David Reese, CEO of Provista, commented: "Provista is committed to advancing the standard of diagnostic care for women at risk or suffering from ovarian and other cancers, and LPA is a potential biomarker that could be critical to achieving this goal. We believe the ability to detect bioactive lipids using Lpath's unique technology will provide a distinct advantage in diagnosing gynecologic cancers."

About Provista Diagnostics
Provista Diagnostics, Inc., develops and commercializes breakthrough, easy-to-administer blood-based diagnostic tests for early oncology-related disease state recognition and detection purposes. The company's focus is on oncology-related diagnostics where a significantly high unmet clinical need exists. Near-term development and commercialization efforts focus on women's cancers such as breast and ovarian cancer. For more about Provista is available at www.provistadx.com.

About Lpath
San Diego-based Lpath, Inc., a therapeutic antibody company, is the category leader in lipid-targeted therapeutics. The company's ImmuneY2™ drug-discovery engine has the unique ability to generate monoclonal antibodies that bind to and inhibit bioactive lipids that contribute to disease. The company is developing three drug candidates: iSONEP™ is being studied in a Phase 2 trial in wet AMD patients; ASONEP™ is being studied in a Phase 2 trial in renal cell carcinoma patients; and Lpathomab is a preclinical drug candidate that holds promise in pain, neurotrauma, and other diseases. For more information, visit www.Lpath.com.


http://www.marketwired.com/press-release/lpath-signs-collaboration-license-agreement-with-provista-diagnostics-develop-cancer-nasdaq-lptn-1765017.htm

"Just One More Thing"

Gold Seeker Said

Dcspka, William Gartner's plan in 2010/2011 was to merge Provista Life Sciences with Radient. and sold the licenses of the breast and ovarian cancer markers to a new company called Provista diagnostics.


I Agree with Gold Seeker ...Wolf Ahoooooooooooooooooo

[lakeshore555]

I am an objective investor. I am not, however, an investor who invests in rumors. I like evidence, especially SEC filings.

I don't see ANY evidence that William Gartner is doing anything with DR-70 or Radient other than trying to get funding for an LLC called Global Cancer Diagnostics that, if funded, would attempt to sell DR-70 on the internet.

There is no evidence that William Gartner has been a driving force in biotech for many years. There is some conjecture, and perhaps some wishful thinking, that Gartner is successfully doing something, but the evidence I see is the following:

* Radient filed an 8-K in 2012 saying GCDX didn't get funding and the agreement was cancelled.

* GCDx does not reply to emails and their voice mailbox has been full for well over a year.

* GCDx entered a contest on Fundable in 2013 but dropped out after raising only $200.

* Gartner promised to start selling DR-70 on his website in June 2012 but it never happened.

* GCDx applied for a TRADEMARK, but owns no patent.

So to be clear, I am not DOWNPLAYING Gartner's "Role as driving force between bringing together the Takeover Group, Provista, RXPC, Amarantus, GCDx, and Dignyte." I am saying there is nothing TO downplay.

The takeover rumor is over three years old now. It was created in March 2011. This rumor no longer has legs, IMO. Without some hard evidence, like a Schedule 13 or a press release or an SEC filing, I think it's folly to keep believing a rumor like this. That does NOT mean I am not objective.